title: Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.
abstract: Ivermectin is a macrocyclic lactone that acts as a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors (nAChRs) but has no modulatory activity on 5-hydroxytryptamine (5-HT) type 3 (5-HT(3)) receptors. By examining the influence of ivermectin on subunit chimeras containing domains from the nAChR alpha7 subunit and the 5-HT3A subunit, we have concluded that the transmembrane domains play a critical role in influencing allosteric modulation by ivermectin. A series of mutations located within the alpha-helical transmembrane domains of the alpha7 subunit were examined, and seven were found to have significant effects on allosteric modulation by ivermectin. Four mutations (A225D, Q272V, T456Y, and C459Y) caused a significant reduction in the potency of ivermectin as an allosteric potentiator. Compared with wild-type alpha7 nAChRs, potentiation by ivermectin was reduced dramatically (by 89-97%) by these mutations. Somewhat unexpectedly, three mutations (S222M, M253L, and S276V located in TM1, TM2, and TM3) converted ivermectin from a positive allosteric modulator into an antagonist. Levels of inhibition of 56, 84, and 89% were observed on M253L, S276V, and S222M, respectively. Antagonism by ivermectin was insurmountable and had no effect on EC(50) of acetylcholine, indicating that it is acting noncompetitively. The seven mutations that influence allosteric modulation by ivermectin are located near a predicted intrasubunit transmembrane cavity. Computer docking simulations provide support for the hypothesis that ivermectin binds in close proximity to this cavity. We conclude that transmembrane mutations in alpha7 nAChRs are able to convert ivermectin from a positive to a negative allosteric modulator.
authors.affiliation: Department of Neuroscience, Physiology & Pharmacology, University College London, London, United Kingdom.
authors.forename: Toby
authors.initials: T
authors.lastname: Collins
authors.forename: Neil S
authors.initials: NS
authors.lastname: Millar
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D003198:Computer Simulation; D006801:Humans; D007559:Ivermectin / Q000494:pharmacology*; D017354:Point Mutation; D011978:Receptors, Nicotinic / Q000235:genetics*; D014982:Xenopus laevis
chemical_list: D011978:Receptors, Nicotinic; D007559:Ivermectin
references.citation: Eur J Pharmacol. 2000 Apr 14;394(2-3):163-70
references.pmid: 10771281
references.citation: Vet Hum Toxicol. 2000 Feb;42(1):30-5
references.pmid: 10670084
references.citation: J Neurosci. 2005 Apr 27;25(17):4396-405
references.pmid: 15858066
references.citation: Neuron. 2007 Apr 19;54(2):263-74
references.pmid: 17442247
references.citation: J Pharmacol Exp Ther. 2007 Oct;323(1):294-307
references.pmid: 17625074
references.citation: J Mol Biol. 2006 Jan 13;355(2):310-24
references.pmid: 16307758
references.citation: Neuroscience. 2000;101(3):785-91
references.pmid: 11113327
references.citation: J Parasitol. 1995 Apr;81(2):286-94
references.pmid: 7707209
references.citation: J Biol Chem. 1998 Feb 6;273(6):3314-9
references.pmid: 9452448
references.citation: J Biol Chem. 2002 Jan 18;277(3):2000-5
references.pmid: 11714703
references.citation: Br J Pharmacol. 2008 Mar;153 Suppl 1:S177-83
references.pmid: 18246096
references.citation: Pflugers Arch. 2008 Aug;456(5):939-50
references.pmid: 18427835
references.citation: Neuropharmacology. 2006 Feb;50(2):174-81
references.pmid: 16225893
references.citation: J Mol Biol. 2007 Jun 15;369(4):895-901
references.pmid: 17481657
references.citation: Eur J Pharmacol. 1994 Jul 1;259(2):121-8
references.pmid: 7957605
references.citation: J Neurochem. 1998 Jun;70(6):2585-93
references.pmid: 9603225
references.citation: J Biol Chem. 2001 Apr 20;276(16):12556-64
references.pmid: 11278873
references.citation: J Neurophysiol. 1994 Sep;72(3):1317-26
references.pmid: 7807214
references.citation: Nat Rev Drug Discov. 2002 Jun;1(6):427-36
references.pmid: 12119744
references.citation: Mol Pharmacol. 2003 Feb;63(2):419-28
references.pmid: 12527814
references.citation: Mol Pharmacol. 1987 Dec;32(6):749-52
references.pmid: 2447480
references.citation: Br J Pharmacol. 2007 Oct;152(4):501-12
references.pmid: 17721553
references.citation: Mol Pharmacol. 2005 Nov;68(5):1431-8
references.pmid: 16120769
references.citation: Mol Pharmacol. 2007 Feb;71(2):389-97
references.pmid: 17065235
references.citation: J Mol Biol. 2005 Mar 4;346(4):967-89
references.pmid: 15701510
references.citation: J Pharmacol Exp Ther. 2003 Jun;305(3):1024-36
references.pmid: 12649296
references.citation: Nature. 2003 Jun 26;423(6943):949-55
references.pmid: 12827192
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1155-63
references.pmid: 17707779
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14686-91
references.pmid: 18791069
references.citation: Neuropharmacology. 2002 Sep;43(3):374-84
references.pmid: 12243767
references.citation: J Neurosci. 1999 Sep 1;19(17):7289-99
references.pmid: 10460235
references.citation: Nature. 1997 Sep 25;389(6649):385-9
references.pmid: 9311780
references.citation: Mol Pharmacol. 2008 Nov;74(5):1407-16
references.pmid: 18678621
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):836-43
references.pmid: 19549506
references.citation: Nature. 2006 Nov 23;444(7118):486-9
references.pmid: 17108970
references.citation: Med Res Rev. 2007 Sep;27(5):723-53
references.pmid: 17238157
references.citation: Hum Mol Genet. 2003 Nov 15;12(22):3017-24
references.pmid: 14506129
references.citation: J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17
references.pmid: 16738207
references.citation: Mol Pharmacol. 1998 Feb;53(2):283-94
references.pmid: 9463487